Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC. Wise-Draper TM, et al. Among authors: desai p. Target Oncol. 2017 Jun;12(3):323-332. doi: 10.1007/s11523-017-0482-9. Target Oncol. 2017. PMID: 28357727 Free PMC article. Clinical Trial.
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM. Gulati S, et al. Cancer. 2020 Jan 15;126(2):354-362. doi: 10.1002/cncr.32539. Epub 2019 Oct 18. Cancer. 2020. PMID: 31626727 Free PMC article. Clinical Trial.
A Phase 0/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
Desai PB, Karve AS, Zawit M, Arora P, Dave N, Awosika J, Li N, Fuhrman B, Medvedovic M, Sallans L, Kendler A, DasGupta B, Plas D, Curry R, Zuccarello M, Chaudhary R, Sengupta S, Wise-Draper TM. Desai PB, et al. Clin Cancer Res. 2024 May 15;30(10):2068-2077. doi: 10.1158/1078-0432.CCR-23-3341. Clin Cancer Res. 2024. PMID: 38530160 Clinical Trial.
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.
Mishra R, Yuan L, Patel H, Karve AS, Zhu H, White A, Alanazi S, Desai P, Merino EJ, Garrett JT. Mishra R, et al. Among authors: desai p. Int J Mol Sci. 2021 Feb 19;22(4):2088. doi: 10.3390/ijms22042088. Int J Mol Sci. 2021. PMID: 33669867 Free PMC article.
1,708 results